Screener
Aclaris Therapeutics ACRS Drug Candidate Modzatinib — Research And Development Project Spend
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept acrs:ResearchAndDevelopmentProjectSpend.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| (In thousands) | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Research and development: | ||||
| Bosakitug | 3,335 | 2,847 | 6,476 | 6,231 |
| ATI-052 | 4,899 | 1,418 | 8,080 | 2,037 |
| Modzatinib | 370 | 1,118 | 861 | 2,926 |
| ATI-9494 | 3,056 | 871 | 5,281 | 1,549 |
| Discovery | 1,972 | 749 | 3,411 | 1,417 |
| Total research and development project expense(1) | 13,632 | 7,003 | 24,109 | 14,160 |
| Personnel | 3,036 | 2,984 | 6,317 | 5,911 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's drug candidate modzatinib — research and development project spend?
- Aclaris Therapeutics (ACRS) reported drug candidate modzatinib — research and development project spend of $370K in Q2 2026.
- What does drug candidate modzatinib — research and development project spend mean?
- This metric represents the total direct and allocated costs incurred by the company to advance the research and development of the specific drug candidate, Modzatinib. It encompasses expenses related to clinical trials, preclinical studies, regulatory filings, and manufacturing process development for this asset. Monitoring this spend provides insight into the company's capital allocation strategy and the progress of its pipeline toward potential commercialization.
Ask your AI about Aclaris Therapeutics's drug candidate modzatinib — research and development project spend.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude